GSK's pill, the first oral antibiotic for urinary tract infections in almost 30 years, comes as bacteria are increasingly ...

GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of ...

Now, after nearly three decades, the U.S. Food and Drug Administration (FDA) has approved Blujepa (gepotidacin), a new oral antibiotic from GSK, offering fresh hope for those struggling with ...

The U.S. Food and Drug Administration has approved Blujepa (gepotidacin) for the treatment of uncomplicated urinary tract ...

The FDA has approved GSK’s Blujepa for the treatment of female adults and pediatric patients with uncomplicated urinary tract ...

Blujepa is the first in a new class of oral antibiotics in 30 years. It is expected to launch in the second half of 2025 in the United States.

“The approval of Blujepa is a crucial milestone with uUTIs among the most common infections in women,” said Tony Wood, Chief Scientific Officer, GSK. “We are proud to have developed ...

The Food and Drug Administration (FDA) has approved a new drug, Blujepa, the first of a new class of oral antibiotics for treating UTIs, to head to market. Drugmaker GSK plans to release the ...

GSK received approval from the Food and Drug Administration for Blujepa to be used as a treatment for some urinary tract infections. Blujepa, or gepotidacin, was approved to treat uncomplicated ...